Japan Tobacco (2914) · InitiativeAchieved
Complete Outsourcing of Pharmaceutical Manufacturing
First written in FY2019. 1 of 3 entries say "Advanced", first in FY2020-Q3. Latest entry: FY2020.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Pharmaceutical Manufacturing Using Contract ManufacturingA theme 2 companies write about · 1 as a headwind · 1 as a tailwind
0 other companies' latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020AchievedAnnual report
「As we discontinued manufacturing at our Group plants in 2020, all stages of manufacturing our Group products are outsourced.」
For pharmaceutical manufacturing, production at Group plants was discontinued in 2020 and outsourcing of all stages was completed. - FY2020-Q3AdvancedAnnual report
「This resulted from the transfer of the Sakura Plant, which had been owned by Group company Torii Pharmaceutical Co., Ltd.」
In connection with the move toward fully outsourced pharmaceutical manufacturing, the transfer of the Sakura Plant owned by Torii Pharmaceutical was disclosed as a change in property, plant and equipment. - FY2019First statedAnnual report
「In addition, we plan to discontinue manufacturing at Torii Pharmaceutical during fiscal 2020 and switch entirely to outsourced manufacturing.」
In the pharmaceutical business, the plan to discontinue manufacturing at Torii Pharmaceutical during fiscal 2020 and switch all production to outsourced manufacturing was identified for the first time as a standalone initiative.